# Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/epacadostat-plus-pembrolizumab-versus-placebo-plus-pembrolizumab-in-patients/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Georgina V. Long,Reinhard Dummer,Omid Hamid,Thomas F. Gajewski,Christian Caglevic,Stéphane Dalle,Ana Arance,Matteo S. Carlino,Jean‐Jacques Grob,Tae Min Kim,Lev Demidov,Caroline Robert,James Larkin,James R. Anderson,Janet Maleski,Mark M. Jones,Scott J. Diede,Tara C. Mitchell |
| Citations | 967 |
| DOI | 10.1016/s1470-2045(19)30274-8 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2949375297 |
| PMID | 31221619 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Tae Min Kim](https://scholariq.org/researchers/tae-min-kim/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.